These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20131669)

  • 1. [Safety of cell culture-based influenza vaccines].
    Schmitt HJ; Gregersen JP; Trusheim H; Bröker M
    Med Monatsschr Pharm; 2010 Jan; 33(1):4-10. PubMed ID: 20131669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of MDCK cell culture-based influenza vaccines.
    Gregersen JP; Schmitt HJ; Trusheim H; Bröker M
    Future Microbiol; 2011 Feb; 6(2):143-52. PubMed ID: 21366415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous cell lines as a production system for influenza vaccines.
    Genzel Y; Reichl U
    Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
    J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cell-based backup to speed up pandemic influenza vaccine production.
    Lee MS; Hu AY
    Trends Microbiol; 2012 Mar; 20(3):103-5. PubMed ID: 22257962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
    Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
    Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of a novel influenza vaccine derived from a continuous cell line].
    Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.
    Wood JM; Robertson JS
    Nat Rev Microbiol; 2004 Oct; 2(10):842-7. PubMed ID: 15378048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic influenza: overview of vaccines and antiviral drugs.
    Cox MM
    Yale J Biol Med; 2005 Oct; 78(5):321-8. PubMed ID: 17132338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New vaccine approaches for seasonal and pandemic influenza.
    Palache B
    Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.
    Minor PD
    Clin Infect Dis; 2010 Feb; 50(4):560-5. PubMed ID: 20085485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
    Doroshenko A; Halperin SA
    Expert Rev Vaccines; 2009 Jun; 8(6):679-88. PubMed ID: 19485748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
    Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
    Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1995; 73(4):431-5. PubMed ID: 7554013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring vaccine safety during an influenza pandemic.
    Iskander J; Haber P; Herrera G
    Yale J Biol Med; 2005 Oct; 78(5):265-75. PubMed ID: 17132333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.